5,813 results match your criteria Hypophosphatemia


Randomized trial of intravenous iron-induced hypophosphatemia.

JCI Insight 2018 Dec 6;3(23). Epub 2018 Dec 6.

AMAG Pharmaceuticals, Inc., Waltham, Massachusetts, USA.

Background: Hypophosphatemia can complicate intravenous iron therapy, but no head-to-head trials compared the effects of newer intravenous iron formulations on risks and mediators of hypophosphatemia.

Methods: In a randomized, double-blinded, controlled trial of adults with iron deficiency anemia from February 2016 to January 2017, we compared rates of hypophosphatemia in response to a single FDA-approved course of ferric carboxymaltose (n = 1,000) or ferumoxytol (n = 997). To investigate pathophysiological mediators of intravenous iron-induced hypophosphatemia, we nested within the parent trial a physiological substudy (ferric carboxymaltose, n = 98; ferumoxytol, n = 87) in which we measured fibroblast growth factor 23 (FGF23), calcitriol, and parathyroid hormone (PTH) at baseline and 1, 2, and 5 weeks later. Read More

View Article
December 2018
2 Reads

Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial.

Lancet Infect Dis 2018 Nov 24;18(11):1241-1250. Epub 2018 Oct 24.

Wits RHI, University of the Witwatersrand, Johannesburg, South Africa.

Background: Young women in southern Africa have substantial risk of HIV acquisition. Female-controlled biomedical interventions are needed to mitigate this risk. We aimed to assess the safety and efficacy of a pericoitally applied tenofovir 1% gel. Read More

View Article
November 2018

Lower phosphate levels following pancreatectomy is associated with postoperative pancreatic fistula formation.

HPB (Oxford) 2018 Nov 29. Epub 2018 Nov 29.

Harvard Medical School, 25 Shattuck St., Boston, MA 02115, USA; Massachusetts General Hospital, 55 Fruit St., Boston, MA 02114, USA. Electronic address:

Background: Whereas hypophosphatemia following hepatectomy is associated with decreased morbidity, hypophosphatemia following pancreatectomy may be associated with increased morbidity, including the development of postoperative pancreatic fistula (POPF). This study aimed to evaluate the relationship between postoperative hypophosphatemia and POPF formation.

Methods: Patients from our institutional Research Patient Data Registry who underwent pancreatectomy from 2001 to 2017 were included. Read More

View Article
November 2018

Prevalence of Metabolic Bone Disease in Tube-Fed Children Receiving Elemental Formula.

Horm Res Paediatr 2018 Nov 29:1-8. Epub 2018 Nov 29.

Division of Pediatric Endocrinology, Mayo Clinic, Rochester, Minnesota, USA.

Background: Previous studies suggest normal mineral status in children receiving elemental formula. However, a recent multicenter survey described 51 children who developed hypophosphatemia and bone disease while receiving elemental formula. Our aim is to determine the prevalence of metabolic bone disease in children receiving extensively hydrolyzed or amino acid-based formula. Read More

View Article
November 2018

An Approach to Hypophosphataemia

Ir Med J 2018 May 10;111(5):761. Epub 2018 May 10.

Dept of Endocrinology, St. Vincent’s University Hospital, Elm Park, Dublin 4

View Article

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.

Cancer Discov 2018 Nov 28. Epub 2018 Nov 28.

Hematology-Oncology, Samsung Medical Center.

RET fusions are oncogenic drivers of various tumors, including non-small cell lung cancers (NSCLCs). The safety and antitumor activity of the multikinase RET inhibitor RXDX-105 were explored in a phase I/Ib trial. A recommended phase 2 dose of 275 mg fed daily was identified. Read More

View Article
November 2018
1 Read

Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.

Lancet Oncol 2018 Nov 23. Epub 2018 Nov 23.

Medical Oncology Department, Centre Léon Bérard, Lyon, France.

Background: Regorafenib has proven activity in patients with pretreated gastrointestinal stromal tumours and colorectal and hepatocellular carcinoma. We designed REGOBONE to assess the efficacy and safety of regorafenib for patients with progressive metastatic osteosarcoma and other bone sarcomas. This trial comprised four parallel independent cohorts: osteosarcoma, Ewing sarcoma, chondrosarcoma, and chordoma. Read More

View Article
November 2018
2 Reads

Burosumab in X-linked hypophosphatemia: a profile of its use in the USA.

Drugs Ther Perspect 2018 8;34(11):497-506. Epub 2018 Oct 8.

Springer, Private Bag 65901, Mairangi Bay, 0754 Auckland, New Zealand.

Burosumab (Crysvita), a fully human IgG1 monoclonal antibody directed at fibroblast growth factor 23 (FGF23), is indicated for the treatment of X-linked hypophosphatemia (XLH), a condition associated with excessive FGF23 production. It directly addresses the excessive FGF23 activity in patients with XLH by binding to FGF23, and inhibiting its signaling. This leads to increased gastrointestinal phosphate absorption and renal phosphate reabsorption, thereby improving serum phosphate levels, and, ultimately, bone mineralization and the risk of bone disease. Read More

View Article
October 2018
4 Reads

A case of entecavir-associated bullous fixed drug eruption and a review of literature.

Turk J Gastroenterol 2018 Nov 19. Epub 2018 Nov 19.

Department of Pathology, Necmettin Erbakan University School of Medicine, Konya, Turkey.

Fixed drug eruption (FDE) is a type of drug reaction characterized by localized erythema, hyperpigmentation, and bullous at the same site(s), generally observed following every intake of a causative drug. Delayed-type cellular hypersensitivity (Type IVC) is considered to play a role in FDE etiology. Several antibiotics, barbiturates, oral contraceptives, nonsteroidal anti-inflammatory drugs, laxative-containing phenolphthalein, metronidazole, and quinine are known to be the primary drugs responsible for FDE. Read More

View Article
November 2018
6 Reads

Hypophosphatemic Rickets.

Pediatr Clin North Am 2019 Feb;66(1):179-207

The Research Institute of the McGill University Health Centre, 1001 Boulevard Décarie, Room EM1.2232, Montreal, Quebec H4A3J1, Canada.

Hypophosphatemic rickets, mostly of the X-linked dominant form caused by pathogenic variants of the PHEX gene, poses therapeutic challenges with consequences for growth and bone development and portends a high risk of fractions and poor bone healing, dental problems and nephrolithiasis/nephrocalcinosis. Conventional treatment consists of PO4 supplements and calcitriol requiring monitoring for treatment-emergent adverse effects. FGF23 measurement, where available, has implications for the differential diagnosis of hypophosphatemia syndromes and, potentially, treatment monitoring. Read More

View Article
February 2019
1 Read
2.198 Impact Factor

Predictors of Complications in Anorexia Nervosa and Atypical Anorexia Nervosa: Degree of Underweight or Extent and Recency of Weight Loss?

J Adolesc Health 2018 Dec;63(6):717-723

Department of Adolescent Medicine, The Royal Children's Hospital, Melbourne, Australia; Centre for Adolescent Health, The Royal Children's Hospital, Melbourne, Australia; Department of Paediatrics, The University of Melbourne, Melbourne, Australia; Murdoch Children's Research Institute, Melbourne, Australia.

Purpose: Adolescents with atypical anorexia nervosa (AAN) can experience severe physical complications despite not being underweight, posing questions about the contribution of weight loss to complications experienced in restrictive eating disorders (EDs). This study compared total weight loss and recent weight loss with admission weight as predictors of physical and psychological complications.

Methods: Retrospective (2005-2010) and prospective (2011-2013) studies were undertaken of 12- to 19-year-old hospitalized adolescents with anorexia nervosa (AN) or AAN, defined as meeting criteria for AN except underweight (≥85% median body mass index). Read More

View Article
December 2018
4 Reads

Phosphate homeostasis disorders.

Best Pract Res Clin Endocrinol Metab 2018 Oct 18;32(5):685-706. Epub 2018 Jun 18.

Endocrine Unit and Pediatric Nephrology Unit, Massachusetts General Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. Electronic address:

Our understanding of the regulation of phosphate balance has benefited tremendously from the molecular identification and characterization of genetic defects leading to a number of rare inherited or acquired disorders affecting phosphate homeostasis. The identification of the key phosphate-regulating hormone, fibroblast growth factor 23 (FGF23), as well as other molecules that control its production, such as the glycosyltransferase GALNT3, the endopeptidase PHEX, and the matrix protein DMP1, and molecules that function as downstream effectors of FGF23 such as the longevity factor Klotho and the phosphate transporters NPT2a and NPT2c, has permitted us to understand the complex interplay that exists between the kidneys, bone, parathyroid, and gut. Such insights from genetic disorders have allowed not only the design of potent targeted treatment of FGF23-dependent hypophosphatemic conditions, but also provide clinically relevant observations related to the dysregulation of mineral ion homeostasis in health and disease. Read More

View Article
October 2018
1 Read

Correction to: Hypophosphatemia as a Predictor of Organ-Specific Complications Following Gastrointestinal Surgery: Analysis of 8034 Patients.

World J Surg 2018 Nov 7. Epub 2018 Nov 7.

Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue C-891, New York, NY, 10065, USA.

In the original version of this article, Martin R. Weiser's last name was spelled incorrectly. It is correct as reflected here. Read More

View Article
November 2018
4 Reads

Multicentric insulinoma associated with multiple endocrine neoplasia type 1: One case report

Rev Med Inst Mex Seguro Soc 2018 Oct 25;56(3):316-319. Epub 2018 Oct 25.

Background: Pancreatic neuroendocrine tumors may be associated with multiple endocrine neoplasia type 1 (MEN1) in 15-25% of cases, and up to 10% develop insulinomas, which are the most frequent cause of persistent hyperinsulinemic hypoglycemia in adults. The objective is to show a clinical case that presents this association.

Clinical Case: 36-year-old patient with seizures associated with fasting hypoglycemia of 36 mg/dL. Read More

View Article
October 2018
2 Reads

Physiological regulation of phosphate by vitamin D, parathyroid hormone (PTH) and phosphate (Pi).

Pflugers Arch 2018 Nov 5. Epub 2018 Nov 5.

Centre for Nephrology, University College London (UCL), Royal Free Campus, Rowland Hill Street, London, NW3 2PF, UK.

Inorganic phosphate (Pi) is an abundant element in the body and is essential for a wide variety of key biological processes. It plays an essential role in cellular energy metabolism and cell signalling, e.g. Read More

View Article
November 2018
5 Reads

[Bone and calcium metabolism associated with malignancy. Tumor-induced osteomalacia.]

Authors:
Seiji Fukumoto

Clin Calcium 2018 ;28(11):1451-1455

Fujii Memorial Institute of Medical Sciences, Institute of Advanced Medical Sciences, Tokushima University, Japan.

Tumor-induced osteomalacia(TIO)is a paraneoplastic syndrome caused by excessive production and secretion of fibroblast growth factor 23(FGF23)from causative tumors which induces hypophosphatemia and osteomalacia. Mesenchymal benign tumors in bone or soft tissue are the most frequent causes for TIO. The first choice treatment of TIO is complete resection of the responsible tumors. Read More

View Article
January 2018
2 Reads

Cutaneous Skeletal Hypophosphatemia Syndrome in Association with a Mosaic Mutation.

Ann Clin Lab Sci 2018 Sep;48(5):665-669

Department of Pediatrics, Seoul National University College of Medicine, Seoul National University Children's Hospital, Seoul, Korea

Recent molecular genetic studies have revealed that Schimmelpenning-Feuerstein-Mims syndrome (SFMS), which presents as sebaceous nevi, is a mosaic RASopathy caused by postzygotic somatic activating mutations in , , or Some patients with SFMS also have hypophosphatemic rickets, called cutaneous skeletal hypophosphatemia syndrome (CSHS). We here report a pediatric case of biopsy-proven CSHS with mosaic mutation in the gene. A girl who showed extensive nevus sebaceous since birth had suffered progressive lower extremity deformity since the age of 5 years. Read More

View Article
September 2018
7 Reads

High Incidence of Cranial Synostosis and Chiari I Malformation in Children With X-Linked Hypophosphatemic Rickets (XLHR).

J Bone Miner Res 2018 Oct 23. Epub 2018 Oct 23.

Pediatric Neurosurgery, Hôpital Femme Mère Enfant, Hospices Civiles de Lyon and University Claude Bernard Lyon 1, Bron Cedex, France.

X-linked hypophosphatemic rickets (XLHR) represents the most common form of genetic hypophosphatemia and causes rickets and osteomalacia in children because of increased FGF23 secretion and renal phosphate wasting. Even though cranial vault and craniovertebral anomalies of potential neurosurgical interest, namely early closure of the cranial sutures and Chiari type I malformation, have been observed in children with XLHR, their actual incidence and characteristics are not established. The aims of this study were to analyze the incidence of cranial and cervico-occipital junction (COJ) anomalies in children with XLHR and describe its features. Read More

View Article
October 2018
8 Reads

TINU-associated Fanconi syndrome: a case report and review of literature.

BMC Nephrol 2018 Oct 19;19(1):274. Epub 2018 Oct 19.

Department of internal medicine and infectious diseases, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, 10 Av. Hippocrate, 1200, Brussels, Belgium.

Background: Tubulo-interstitial Nephritis and Uveitis (TINU) syndrome is a rare oculo-renal inflammatory disease. Renal tubular defects are usually found, but full proximal tubular abnormalities have rarely been described.

Case Presentation: We report the case of a 55-year old woman, native from Morocco, presenting with bilateral, non-granulomatous, anterior uveitis, mild renal insufficiency, leucocyturia and glycosuria. Read More

View Article
October 2018
1 Read

A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease.

Leuk Res 2018 Nov 9;74:89-96. Epub 2018 Oct 9.

H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States.

Purpose: Preclinical evidence indicates that the bone marrow microenvironment provides a protective niche for leukemic stem cells, allowing them to evade the effects of BCR-ABL tyrosine kinase inhibitors (TKIs), but that targeting of the JAK-STAT pathway with the JAK2 inhibitor ruxolitinib increases TKI-induced apoptosis. A phase I clinical trial (NCT01702064) investigated the tolerability and safety of treating chronic-phase chronic myeloid leukemia patients with ruxolitinib in combination with the BCR-ABL TKI nilotinib and explored initial efficacy evidence.

Experimental Design: Eleven patients already treated with single-agent nilotinib (300-400 mg twice daily) commenced combination therapy, and molecular responses were evaluated after 6 months. Read More

View Article
November 2018
4 Reads
2.350 Impact Factor

Electrolyte and Acid-Base Disorders in the Renal Transplant Recipient.

Front Med (Lausanne) 2018 2;5:261. Epub 2018 Oct 2.

Department of Medicine, University of Pittsburgh, Pittsburgh, PA, United States.

Kidney transplantation is the current treatment of choice for patients with end-stage renal disease. Innovations in transplantation and immunosuppression regimens have greatly improved the renal allograft survival. Based on recently published data from the Scientific Registry of Transplant recipients, prevalence of kidney transplants is steadily rising in the United States. Read More

View Article
October 2018
7 Reads

Adverse events risk associated with regorafenib in the treatment of advanced solid tumors: meta-analysis of randomized controlled trials.

Onco Targets Ther 2018 2;11:6405-6414. Epub 2018 Oct 2.

Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China,

Background: Regorafenib is a novel multikinase inhibitor (MKI) approved for use in the treatment of metastatic colorectal cancer (CRC), treatment-refractory gastrointestinal stromal tumors, and other solid tumor malignancies. However, the adverse events (AEs) associated with regorafenib have not been systematically investigated. Hence, we performed a meta-analysis to identify AEs associated with regorafenib in patients with advanced solid tumors. Read More

View Article
October 2018
7 Reads

Analysis of opossum kidney NaPi-IIc sodium-dependent phosphate transporter to understand Pi handling in human kidney.

Clin Exp Nephrol 2018 Oct 13. Epub 2018 Oct 13.

Department of Molecular Nutrition, Institute of Biomedical Sciences, University of Tokushima Graduate School, 3-18-15 Kuramoto-cho, Tokushima, 770-8503, Japan.

Background: The role of Na-dependent inorganic phosphate (Pi) transporters in the human kidney is not fully clarified. Hereditary hypophosphatemic rickets with hypercalciuria (HHRH) is caused by loss-of-function mutations in the IIc Na-dependent Pi transporter (NPT2c/Npt2c/NaPi-IIc) gene. Another Na-dependent type II transporter, (NPT2A/Npt2a/NaPi-IIa), is also important for renal Pi reabsorption in humans. Read More

View Article
October 2018
3 Reads

A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials.

Eur J Cancer 2018 Nov 10;104:32-38. Epub 2018 Oct 10.

The Royal Marsden NHS Foundation Trust, Downs Rd, Sutton, SM2 5PT, London, UK; The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG, London, UK. Electronic address:

Background: The incidence and clinical significance of electrolyte abnormalities (EAs) in phase I clinical trials are unknown. The objective of this study is to evaluate the incidence and severity of EAs, graded according to CTCAE, v4.03, to identify variables associated with EAs and their prognostic significance in a phase I population. Read More

View Article
November 2018
2 Reads

Elemental formula associated hypophosphataemic rickets.

Clin Nutr 2018 Sep 28. Epub 2018 Sep 28.

Department of Endocrinology and Diabetes, Birmingham Children's Hospital, Birmingham, UK; Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK. Electronic address:

Objectives: Hypophosphataemic rickets (HR) is usually secondary to renal phosphate wasting but may occur secondary to reduced intake or absorption of phosphate. We describe a series of cases of HR associated with the use of Neocate, an amino-acid based formula (AAF).

Methods: A retrospective review of cases with HR associated with AAF use presenting to centres across the United Kingdom. Read More

View Article
September 2018
2 Reads

[Analysis of PHEX gene mutations in three pedigrees affected with hypophosphatemic rickets].

Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2018 Oct;35(5):644-647

Laboratory of Medical Genetics, Huai'an Maternal and Child Health Hospital, Huai'an, Jiangsu 223002, China.

Objective: To explore the molecular basis for three pedigrees affected with hypophosphatemia vitamin D resistant rickets (X-linked hypophosphatemia, XLH).

Methods: Peripheral blood samples from the three pedigrees were collected. Following DNA extraction, the 11 exons and flanking regions of the PHEX gene were subjected to PCR amplification and direct sequencing. Read More

View Article
October 2018
1 Read

Phosphaturic mesenchymal tumor and related wound problem.

Medicine (Baltimore) 2018 Oct;97(40):e12507

Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai.

Introduction: Phosphaturic mesenchymal tumor mixed connective tissue type (PMT/MCT) is the most common type (up to 90%) of phosphaturic mesenchymal tumor (PMT), a rare clinicopathologic entity. Besides overproduction of fibroblast growth factor 23 (FGF23), there is a big variation of immunohistochemical characteristic across types of PMT, which makes it difficult to obtain an early diagnosis of PMT/MCT. As a benign tumor, PMT/MCT usually happens in subcutaneous tissues and leads to nonhealing of wound. Read More

View Article
October 2018
7 Reads

Serum Calcium to Phosphorous (Ca/P) Ratio Is a Simple, Inexpensive, and Accurate Tool in the Diagnosis of Primary Hyperparathyroidism.

JBMR Plus 2018 Mar 2;2(2):109-117. Epub 2017 Nov 2.

Unit of Endocrinology, Department of Internal Medicine, Endocrinology, Metabolism, and Geriatrics Azienda Ospedaliero-Universitaria di Modena, Ospedale Civile di Baggiovara Modena Italy.

Primary hyperparathyroidism (PHPT) diagnosis is challenging and is based on serum calcium (Ca) and parathyroid hormone (PTH). Because serum Ca and phosphorous (P) are inversely related in PHPT, we investigated the diagnostic value of the serum Ca/P ratio in the diagnosis of PHPT. We report a single-center, case-controlled, retrospective study including 97 patients with documented PHPT and compared them with those of 96 controls (C). Read More

View Article
March 2018
3 Reads

Genetic Risk Factors for Atypical Femoral Fractures (AFFs): A Systematic Review.

JBMR Plus 2018 Jan 3;2(1):1-11. Epub 2018 Jan 3.

Department of Medicine School of Clinical Sciences Monash University Clayton Australia.

Atypical femoral fractures (AFFs) are uncommon and have been associated particularly with long-term antiresorptive therapy, including bisphosphonates. Although the pathogenesis of AFFs is unknown, their identification in bisphosphonate-naïve individuals and in monogenetic bone disorders has led to the hypothesis that genetic factors predispose to AFF. Our aim was to review and summarize the evidence for genetic factors in individuals with AFF. Read More

View Article
January 2018
2 Reads

[Rickets/Osteomalacia. Anti-FGF23 antibody therapy in patients with FGF23-related hypophosphatemic rickets and osteomalacia.]

Authors:
Yuka Kinoshita

Clin Calcium 2018;28(10):1373-1379

Division of Nephrology & Endocrinology, Department of Medicine, The University of Tokyo Hospital, Japan.

Fibroblast growth factor 23(FGF23)is a phosphaturic hormone, and its excess causes several kinds of congenital and acquired hypophosphatemic diseases. A combination of oral active vitamin D3 and phosphate salt is the current standard therapy for patients with FGF23-related hypophosphatemic rickets and osteomalacia. However, these medications may cause long-term complications, such as secondary hyperparathyroidism and chronic kidney disease. Read More

View Article
January 2018
2 Reads

[Rickets/Osteomalacia. Diagnosis of tumor-induced osteomalacia.]

Clin Calcium 2018;28(10):1351-1357

Department of Nephrology and Endocrinology, The University of Tokyo Hospital, Japan.

Tumor-induced osteomalacia is a fibroblast growth factor 23(FGF23)-related hypophosphatemic disorder caused by FGF23 producing tumor. TIO represents bone pain, fracture/pseudofracture, muscle weakness, etc which could lead the patient bedridden. Serum phosphate level of these patients is low with concomitant inappropriately elevated FGF23 level. Read More

View Article
January 2018
8 Reads

Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors.

J Immunother Cancer 2018 Sep 25;6(1):93. Epub 2018 Sep 25.

Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium.

Background: This open-label, first-in-human, phase 1 study evaluated the safety, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of AMG 228, an agonistic human IgG1 monoclonal antibody targeting glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR), in patients with refractory advanced solid tumors.

Methods: AMG 228 was administered intravenously every 3 weeks (Q3W). Dose escalation was in two stages: single-patient cohorts (3, 9, 30, and 90 mg), followed by "rolling six" design (n = 2-6; 180, 360, 600, 900, and 1200 mg). Read More

View Article
September 2018
5 Reads

Congenital hypophosphataemia in adults: determinants of bone turnover markers and amelioration of renal phosphate wasting following total parathyroidectomy.

J Bone Miner Metab 2018 Sep 20. Epub 2018 Sep 20.

UCD School of Medicine and Medical Science, University College Dublin, Dublin, Ireland.

Congenital hypophosphataemia (CH) is a collection of disorders that cause defective bone mineralisation manifesting with rickets in childhood and osteomalacia in adulthood. Bone turnover markers (BTMs) are surrogate measures of metabolic bone disease severity. We explored the utility of BTMs in 27 adults with CH: 23 had X-linked hypophosphataemia (XLH), of whom 2 were hypoparathyroid post-total parathyroidectomy (PTx); 2 had autosomal dominant hypophosphataemic rickets (ADHR), and 2 had none of the known mutations. Read More

View Article
September 2018
1 Read

[A Case of Hypophosphatemia Induced by Administration of Amrubicin in a Patient with Small Cell Lung Cancer].

Gan To Kagaku Ryoho 2018 Sep;45(9):1369-1371

Dept. of Pharmacy, Ichinomiya Municipal Hospital.

A man in his 50s with small cell lung cancer received amrubicin as the fourth-line therapy from August 201X-1. Serum phosphorus levels before treatment were normal at 2.9mg/dL, but grade 2 hypophosphatemia(2. Read More

View Article
September 2018
1 Read

Serum phosphate and phosphate-regulatory hormones in COPD patients.

Respir Res 2018 Sep 20;19(1):183. Epub 2018 Sep 20.

Department of Pneumology and Intensive Care Medicine, University Hospital Aachen, Aachen, Germany.

Background: Fibroblast growth factor 23 (FGF23) regulates phosphate metabolism by increasing renal phosphate excretion and decreasing 1.25-dihydroxyvitamin D synthesis. Reports about hypophosphatemia in patients with chronic obstructive pulmonary disease (COPD) suggest altered phosphate metabolism. Read More

View Article
September 2018
1 Read

Rare Cause of Infantile Hypercalcemia: A Novel Mutation in the SLC34A1 Gene.

Horm Res Paediatr 2018 Sep 18:1-7. Epub 2018 Sep 18.

Background: Under physiological conditions, proximal tubular phosphate reabsorption via NaPi-IIa (and NaPi-IIc) ensures the maintenance of phosphate homeostasis. Impairment of NaPi-IIa, encoded by SLC34A1, is associated with various overlapping clinical syndromes, including hypophosphatemic nephrolithiasis with osteoporosis, renal Fanconi's syndrome with chronic kidney disease, and idiopathic infantile hypercalcemia and nephrocalcinosis.

Methods: A patient was referred to our hospital due to hyponatremia, hyperkalemia, and hypophosphatemia, as well as persistent hypercalcemia after fluid therapy and sodium replacement. Read More

View Article
September 2018
2 Reads

Letter to editor re: Refeeding syndrome in adults receiving total parenteral nutrition: An audit of practice at a tertiary UK centre.

Clin Nutr 2018 Dec 4;37(6 Pt A):2288. Epub 2018 Sep 4.

Dietetics and Nutrition Department, Ng Teng Fong General Hospital, 1 Jurong East Street 21, 609606, Singapore; Nutrition and Dietetics, College of Nursing and Health Sciences, Flinders University, Australia. Electronic address:

View Article
December 2018
1 Read

NAD metabolism and the SLC34 family: evidence for a liver-kidney axis regulating inorganic phosphate.

Pflugers Arch 2018 Sep 14. Epub 2018 Sep 14.

Department of Molecular Nutrition, Institution of Biomedical Science, Tokushima University Graduate School, 3-18-15 Kuramoto, Tokushima, 770-8503, Japan.

The solute carrier 34 (SLC34) family of membrane transporters is a major contributor to Pi homeostasis. Many factors are involved in regulating the SLC34 family. The roles of the bone mineral metabolism factors parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23) in Pi homeostasis are well studied. Read More

View Article
September 2018
1 Read

Long-term renal follow-up of children treated with cisplatin, carboplatin, or ifosfamide: a pilot study.

Pediatr Nephrol 2018 Sep 14. Epub 2018 Sep 14.

Department of Pediatrics, Division of Nephrology, Toronto Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.

Background: Childhood cancer survivors treated with cisplatin, ifosfamide, or carboplatin are at risk for late kidney and blood pressure (BP) abnormalities. Few studies have comprehensively evaluated kidney outcomes and 24-h ambulatory BP monitoring (ABPM) in this population. We aimed to describe chemotherapy-associated acute kidney injury (AKI) and late kidney outcomes using standardized definitions. Read More

View Article
September 2018
1 Read

Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group.

Lancet Oncol 2018 Oct 11;19(10):1360-1371. Epub 2018 Sep 11.

Medical Oncology-Sarcoma Unit, Istituto di Candiolo-Fondazione del Piemonte per l'Oncologia, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Candiolo, Italy; Department of Oncology, University of Torino, Regione Gonzole, Orbassano, Italy.

Background: Trabectedin is an alkylating drug with a unique mechanism of action causing single-strand and double-strand DNA breaks that activate DNA damage-response pathways. Based on our preclinical data, we hypothesised that poly(ADP-ribose) polymerase 1 (PARP1) inhibitors might be an ideal partner of trabectedin and aimed to assess the safety, identify the recommended phase 2 dose, and explore preliminary signs of activity of trabectedin and olaparib combination treatment in patients with bone and soft-tissue sarcoma.

Methods: We did an open-label, multicentre, phase 1b study, recruiting patients from the national Italian sarcoma network aged 18 years and older with histologically confirmed bone and soft-tissue sarcoma progressing after standard treatments with Eastern Cooperative Oncology Group performance status of 1 or less. Read More

View Article
October 2018
5 Reads

Myoglobinuria in two patients with Duchenne muscular dystrophy after treatment with zoledronate: a case-report and call for caution.

Neuromuscul Disord 2018 Oct 10;28(10):865-867. Epub 2018 Aug 10.

Paediatric Neurology and Neurorehabilitation Unit, Lausanne University Hospital (CHUV), Pierre-Decker 5, 1011 Lausanne, Switzerland; Institute of Social and Preventive Medicine, University of Bern, Switzerland.

Rhabdomyolysis with myoglobinuria is a recognized complication of dystrophinopathies. It can be triggered by infections, exercise or volatile anesthetics. To our knowledge, it has never been reported in boys with Duchenne muscular dystrophy (DMD) after the administration of bisphosphonates. Read More

View Article
October 2018
2 Reads

Hypophosphatemia Regulates Molecular Mechanisms of Circadian Rhythm.

Sci Rep 2018 Sep 13;8(1):13756. Epub 2018 Sep 13.

Orthopaedic Research Laboratory, Department of Orthopaedic Surgery, Boston University School of Medicine, Boston, USA.

Transcriptomic analysis showed that the central circadian pathway genes had significantly altered expression in fracture calluses from mice fed a low phosphate diet. This led us to hypothesize that phosphate deficiency altered the circadian cycle in peripheral tissues. Analysis of the expression of the central clock genes over a 24-36 hour period in multiple peripheral tissues including fracture callus, proximal tibia growth plate and cardiac tissues after 12 days on a low phosphate diet showed higher levels of gene expression in the hypophosphatemia groups (p < 0. Read More

View Article
September 2018
14 Reads

Assessment of Biochemical and Densitometric Markers of Calcium-Phosphate Metabolism in the Groups of Patients with Multiple Sclerosis Selected due to the Serum Level of Vitamin D.

Biomed Res Int 2018 23;2018:9329123. Epub 2018 Aug 23.

Department of Neurology, SMDZ in Zabrze, Medical University of Silesia in Katowice, ul. 3-go Maja 13-15, 41-800 Zabrze, Poland.

Background: In addition to the widely known effect of vitamin D (vitD) on the skeleton, its role in the regulation of the immune response was also confirmed.

Aim: The assessment of biochemical and densitometric markers of calcium-phosphate metabolism in the groups of patients with relapsing-remitting multiple sclerosis (RRMS) selected due to the serum level of vitamin D.

Methods: The concentrations of biochemical markers and indices of lumbar spine bone densitometry (DXA) were determined in 82 patients divided into vitamin D deficiency (VitDd), insufficiency (VitDi), and normal vitamin D level (VitDn) subgroups. Read More

View Article
August 2018
1 Read

Pharmacological management of X-linked hypophosphataemia.

Br J Clin Pharmacol 2018 Sep 29. Epub 2018 Sep 29.

Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA.

The most common heritable disorder of renal phosphate wasting, X-linked hypophosphataemia (XLH), was discovered to be caused by inactivating mutations in the phosphate regulating gene with homology to endopeptidases on the X-chromosome (PHEX) gene in 1995. Although the exact molecular mechanisms by which PHEX mutations cause disturbed phosphate handling in XLH remain unknown, focus for novel therapies has more recently been based upon the finding that the bone-produced phosphaturic hormone fibroblast growth factor-23 is elevated in XLH patient plasma. Previous treatment strategies for XLH were based upon phosphate repletion plus active vitamin D analogues, which are difficult to manage, fail to address the primary pathogenesis of the disease, and can have deleterious side effects. Read More

View Article
September 2018
3 Reads

Acquired Fanconi syndrome secondary to light chain deposition disease associated with monoclonal gammopathy of renal significance: A case report.

Medicine (Baltimore) 2018 Sep;97(36):e12027

Department of Nephrology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang.

Rationale: Renal Fanconi syndrome (FS) is a rare complication of monoclonal gammopathy. It is characterized by the impairment of renal proximal tubular function leading to normoglycemic glycosuria, aminoaciduria, hypophosphatemia, hypouricemia and proximal renal tubular acidosis. Renal impairment in monoclonal gammopathy, without fulfilling the criteria of multiple myeloma, is categorized as monoclonal gammopathy of renal significance (MGRS). Read More

View Article
September 2018
4 Reads

Ibuprofen Abuse-A Case of Rhabdomyolysis, Hypokalemia, and Hypophosphatemia With Drug-Induced Mixed Renal Tubular Acidosis.

Kidney Int Rep 2018 Sep 8;3(5):1237-1238. Epub 2018 Jun 8.

Department of Nephrology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.

View Article
September 2018
3 Reads

Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.

Oncologist 2018 Sep 6. Epub 2018 Sep 6.

Department of Oncology, Fondazione Poliambulanza, Brescia, Italy.

Background: In the phase III CORRECT trial, regorafenib significantly improved survival in treatment-refractory metastatic colorectal cancer (mCRC). The CONSIGN study was designed to further characterize regorafenib safety and allow patients access to regorafenib before market authorization.

Methods: This prospective, single-arm study enrolled patients in 25 countries at 186 sites. Read More

View Article
September 2018
10 Reads

Ferumoxytol for the treatment of iron deficiency anemia.

Expert Rev Hematol 2018 Oct 14;11(10):829-834. Epub 2018 Sep 14.

c Department of Medicine , University of Virigina Health System , Charlottesville , Virignia , USA.

Introduction: Ferumoxytol is a superparamagnetic molecule originally developed as a contrast agent for magnetic resonance imaging. Elemental iron is contained within the carbohydrate core and is released slowly after infusion allowing a large dose of iron to be administered in a short period of time. Ferumoxytol, originally approved for iron deficiency in chronic kidney disease, received a broad label for any cause of iron deficiency after oral iron intolerance or in those circumstances when oral iron is ineffective or harmful. Read More

View Article
October 2018
6 Reads

Mortality and Recovery of Renal Function in Acute Kidney Injury Patients Treated with Prolonged Intermittent Hemodialysis Sessions Lasting 10 versus 6 Hours: Results of a Randomized Clinical Trial.

Int J Nephrol 2018 13;2018:4097864. Epub 2018 Aug 13.

Botucatu School of Medicine, University of São Paulo State (UNESP), Brazil.

Purpose: This trial aimed to compare mortality and recovery of renal function in acute kidney injury (AKI) patients treated with different durations of prolonged hemodialysis (PHD) sessions (6 h versus 10 h).

Methodology: We included patients with sepsis-associated AKI, >18 years, who are in use of a norepinephrine (lower than 0.7 ucg/kg/min). Read More

View Article
August 2018
1 Read

Yield of diagnostic tests in unexplained renal hypophosphatemia: a case series.

BMC Nephrol 2018 Sep 4;19(1):220. Epub 2018 Sep 4.

Department of Nephrology, Radboud university medical center, Nijmegen, The Netherlands.

Background: Isolated renal hypophosphatemia may be inherited or acquired. An increasing number of patients with unexplained renal hypophosphatemia is being referred to our clinics, but the optimal diagnostic work-up is not known. Therefore, the aim of this study was to assess the diagnostic yield in these patients. Read More

View Article
September 2018
12 Reads